For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvo virus disease and canine parainfluenza virus infection.
Lyophilisate and solvent for suspension for injection
Reg. No. G2377 (Act 36/1947)
Namibia Reg. No. V97/24.1/900 [NS2]
Only for use by or under the supervision of persons registered in terms of, or authorised in terms of, Section 23 (1) (c) of the Veterinary and Para-Veterinary Professions Act, 1982 (Act 19 of 1982).
For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvovirus disease and canine parainfluenza virus infection.
Each vial of the lyophilised substance contains live, attenuated strains of:
- canine distemper virus (CDV) not less than 104 TCID50,
- canine adenovirus type 2 (CAV2) not less than 104 TCID50,
- canine parvovirus (CPV) not less than 107 TCID50 and
- canine parainfluenza virus (CPI) not less than 105,5 TCID50 and each vial contains a single dose for reconstitution.
- Store between 2 °C – 8 °C in a refrigerator.
- Do not freeze.
- Protect from light.
- Avoid prolonged or repetitive exposure to high ambient temperatures.
- Allow the vaccine to gradually reach room temperature (20 °C to 25 °C) prior to use.
- Do not store partially used containers for future use, and use the entire contents once opened.
- After reconstitution, the vaccine should be used within 30 minutes.
- Vaccinate healthy dogs and puppies only.
- Pregnant animals may be vaccinated.
- Following initial vaccination, dogs should not be exposed to infection for at least 14 days.
- In case of accidental self-injection may lead to severe allergic reactions. Seek medical advice immediately and show the package leaflet to the physician.
- Experience has shown that maternal parvovirus antibody status of the puppies in a litter varies greatly and reliance should not be placed on serological examination of the bitch alone.
- KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
- Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
- Observe aseptic precautions. Ensure that all vaccination equipment (containers, syringes and needles) is clean and sterile prior to and during use. Use sterile equipment when administering the vaccine.
- Avoid intravenous injection.
- Avoid contamination of the vaccine with traces of disinfectant and spirits.
- As with all vaccines, hypersensitivity or anaphylactic reactions may occur.
- It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.
- Destroy any unused vaccine and dispose of all the empty vaccine containers and disposable equipment after use in accordance with National Environmental Management: Waste Act, 2008 (Act No. 59 of 2008).
- Do not contaminate rivers, dams or any water sources with containers or waste.
DIRECTIONS FOR USE – USE ONLY AS DIRECTED
The following recommendations are included since it is likely that immunisation with Nobivac® DHPPi will form part of a more comprehensive vaccination programme.
At 4 to 6 weeks: Nobivac® Puppy DP (G2323).
Then, 3 to 4 weeks later: Nobivac® DHPPi with or withoutNobivac® Lepto (G2200).
And 3 to 4 weeks thereafter: Nobivac® DHPPi and Nobivac® Rabies* (G2207) or Nobivac®
RL* (G2199) if Nobivac® Lepto (G2200) was used previously.
* Nobivac® Rabies* (G2207) and Nobivac® RL (G2199) only to be used from 12 weeks of age.
It is recommended that dogs be revaccinated against:
- Canine distemper, canine hepatitis, canine parvovirus infection – 3 years.
- Canine parainfluenza virus infection – every year.
- Rabies – every 3 years (it may be modified to comply with local regulations).
DOSAGE AND ADMINISTRATION
The contents of 1 vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute the Nobivac® DHPPi immediately prior to use by adding the contents of 1 vial (1,0 mℓ) of any of the following:
Nobivac® Lepto (G2200), Nobivac® Rabies (G2207) or Nobivac® Solvent.
The vials are of hydrolytical Type I glass (Ph. Eur.) and are closed with halogenated butyl rubber stoppers (Ph. Eur.) and sealed with coded aluminium caps.
Vials are packed in in polyethylene terephthalate (PET) trays or in cardboard boxes containing 10 or 50 single dose vials.
Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
Tel: +27 (0) 11 923 9300
DATE OF PUBLICATION OF PACKAGE INSERT
03 September 2014
|Zimbabwe Reg. No. E97/80.23.15/9470 |
Veterinary Classification: 802315
Distribution Category: PP